Prostate cancer continues to be a leading cause of cancer mortality in men. The American Cancer Society estimates that approximately 220,800 new cases will be diagnosed and 27,540 men will die from prostate cancer in 2015 in the United States.
› The phi test is more specific for the detection of clinically significant prostate cancer than free and/or total PSA › Increasing phi scores predict a greater risk of high-risk pathology and biochemical recurrence after radical prostatectomy › The phi test performed at the initiation and during the course of active surveillance predicts subsequent biopsy reclassification
Article Conclusion:
Numerous large, prospective studies from geographically diverse regions have consistently demonstrated that phi is more specific for prostate cancer detection than existing standard reference tests of total and free PSA. Increasing phi scores predict a greater risk of clinically significant disease on biopsy and adverse prostatectomy outcomes. The authors investigated whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer overdiagnosis.
Study Overview:
› From the multi-center prospective trial, 658 men aged 50 years or older were identified with PSA 4 to 10 ng/mL and normal digital rectal examination who underwent prostate biopsy › In this population, the performance of PSA, % free PSA, p2PSA and phi were compared to predict biopsy results and, specifically, the presence of clinicallysignificant prostate cancer using multiple criteria
Key Points:
› Results showed that phi was significantly higher in men with Gleason 7 or greater and "Epstein significant" cancer › On ROC analysis, phi had the highest AUC for overall cancer, Gleason 7 or greater and significant cancer (see table below) › At the 90% sensitivity cut off point for phi (a score less than 28.6) 30.1% of patients could have been spared an unnecessary biopsy for benign disease or insignificant cancer compared to 21.7% using % free PSA 
Article Conclusion:
The phi test outperforms its individual components of total, free and p2PSA for the identification of clinically-significant prostate cancer. The Prostate Health Index may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.
› Increased phi levels were strongly associated with patients harboring more aggressive diseases › Furthermore, phi demonstrated potential ability to identify the progress of low-risk localized cancer under active surveillance › The phi test also showed potential association with probability of metastatic progression and biochemical recurrence after radical prostatectomy › Studies showed that if phi was added to the current prostate cancer screening strategies, overall reductions in cost can be achieved due to the reduction in the total number of office visits, laboratory tests and unnecessary biopsies
Studies suggest that phi enhances the accuracy of detection, reduces the number of unnecessary biopsies and helps predict the aggressiveness of prostate cancer when compared to total PSA and free PSA. 
